Keeley Teton Advisors LLC Sells 27,726 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Keeley Teton Advisors LLC cut its stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 32.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,999 shares of the medical equipment provider's stock after selling 27,726 shares during the period. Keeley Teton Advisors LLC owned 0.13% of AxoGen worth $939,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new position in AxoGen in the 4th quarter worth about $30,000. US Bancorp DE bought a new stake in shares of AxoGen during the 4th quarter worth $30,000. Harvest Fund Management Co. Ltd acquired a new position in shares of AxoGen in the 4th quarter worth $93,000. Fox Run Management L.L.C. acquired a new stake in shares of AxoGen during the fourth quarter worth $169,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of AxoGen by 238.6% during the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider's stock valued at $172,000 after purchasing an additional 8,656 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

AxoGen Stock Down 4.2 %

AxoGen stock traded down $0.65 during trading hours on Monday, hitting $14.92. The company had a trading volume of 127,697 shares, compared to its average volume of 425,836. The firm's fifty day moving average is $17.65 and its 200-day moving average is $16.13. The firm has a market capitalization of $661.61 million, a P/E ratio of -46.63 and a beta of 1.00. AxoGen, Inc. has a fifty-two week low of $5.55 and a fifty-two week high of $21.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Insider Buying and Selling

In other news, Director Amy Mcbride Wendell sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the sale, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the transaction, the insider now owns 217,762 shares in the company, valued at $3,810,835. This represents a 6.49 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on AXGN. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $24.00 price objective on shares of AxoGen in a research note on Wednesday, March 5th. Lake Street Capital started coverage on shares of AxoGen in a research report on Monday, March 17th. They set a "buy" rating and a $30.00 price objective on the stock. Finally, Canaccord Genuity Group increased their target price on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $22.60.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.